Advertisement

Topics

Vernalis Company Profile

09:42 EDT 20th June 2018 | BioPortfolio

Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.

Location

Oakdene Court
613 Reading Road
Winnersh
Surrey
RG41 5UA
United Kingdom

Contact

Phone: +44 (0)118 977 3133
Fax: +44 (0)118 989 9300


News Articles [9 Associated News Articles listed on BioPortfolio]

BRIEF—Vernalis looking for a buyer of the company

Further to the company’s announcement on February 28, 2018, UK-based Vernalis, management has admitted…

Vernalis (VER) - Tuzistra XR downgrade prompts strategic rethink

Edison Investment Research - Pharmaceutical & healthcare - Vernalis: Vernalis has provided a trading and operational update to its guidance for Tuzistra XR prescriptions for financial year-end 2018. D...

Vernalis Seeks Buyers, CEO To Step Down, As US Commercial Strategy Disappoints

Disappointing sales growth of its prescription extended-release cough-and-cold product has led Vernalis to decide to close down its US commercial...   

Vernalis receives next veto by FDA

Vernalis reports ‘slower than hoped for’ sales of its cough and cold drug Tuzistra XR

The total number of Tuzistra XR prescriptions for the current financial year is expected to be below the guided range of 105,000 -11,000

Shore Capital Stockbrokers Limited: Form 8.5 (EPT/RI) - Vernalis Plc

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the 'Code')1. KEY ...

Invesco Ltd.: Form 8.3 - Vernalis PLC

Opening Position Disclosure FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (...

2018 Migraine Pipeline Drugs Market Assessment Featuring Alder Pharma, Allergan, Amgen Biopharmaceuticals, Eli Lilly, GSK Impax Laboratories, Pfizer, Teva Pharmaceutical & Vernalis

DUBLIN, Feb. 6, 2018 /PRNewswire/ -- The "Migraine Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2022" report has been added...

Drugs and Medications [0 Results]

None

PubMed Articles [4 Associated PubMed Articles listed on BioPortfolio]

Effect of environmental factors on the germination and emergence of Salvia verbenaca L. cultivars (verbenaca and vernalis): An invasive species in semi-arid and arid rangeland regions.

Salvia verbenaca (wild sage) is a commonly cultivated herbal medicine plant, which is native to the Mediterranean climate regions of Europe, Africa, Asia and the Middle East. However, it has become an...

Amblyospora khaliulini (Microsporidia: Amblyosporidae): Investigations on its life cycle and ecology in Aedes communis (Diptera: Culicidae) and Acanthocyclops vernalis (Copepoda: Cyclopidae) with redescription of the species.

A multi-year study was conducted to examine the natural ecology of the microsporidium Amblyospora khaliulini and more fully characterize parasite development and histopathology in all stages of its pr...

A simple and effective method for assessing chromatin diminution values in copepods using qPCR.

The value of chromatin diminution (CD) in different species of freshwater cyclopoid copepods can differ significantly. The biological and evolutionary roles of these differences remain unclear. To exp...

Circumscription and phylogeny of the Lepidostromatales (lichenized Basidiomycota) following discovery of new species from China and Africa.

Based on an exhaustive sampling of all known Lepidostromatales, a lineage of clavarioid lichen-forming basidiomycetes, we assess (i) the phylogenetic affinities of the six Chinese species currently ac...

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Vernalis

Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat m...

More Information about "Vernalis" on BioPortfolio

We have published hundreds of Vernalis news stories on BioPortfolio along with dozens of Vernalis Clinical Trials and PubMed Articles about Vernalis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Vernalis Companies in our database. You can also find out about relevant Vernalis Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record